ArticleBiology2025
Luminex MFI-Efforts from a Qualitative to a Quantitative Analysis.
Article in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From thresholds to trajectories: a perspective on reframing alloimmune risk for computational modeling in solid organ transplantation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Luminex multiplex assay for the definition of HLA antibodies was introduced 20 years ago. To date, although the assay is simple and straightforward, the interpretation of the results remains a conundrum. Making use of the so-called mean fluorescence value only does not help since this value is relative, the day-to-day variation is significantly large, and the user variation is beyond acceptable ranges. Within the same range of problems, the cutoff value used to classify HLA-specific antibodies as being either present or absent varies between laboratories. This threshold influences clinical decision-making. In addition, the readout value is used to diagnose the amount of HLA-specific antibodies after treatments like absorption, plasmapheresis, or transplantation, overlooking the relative nature of the value. In this study, we show bead variability for HLA class I and HLA class II based on negatively defined bead reactions with a mean fluorescence value below 1500 and self-antigens. In an effort to circumvent the assay's inherent problems, we introduced the term ratio. For each serum sample, a paired sample from before the treatment is run in parallel. The ratio of post-treatment to pre-treatment can then be used to characterize antibody dynamics: a ratio above 1 reflects increased antibody production and a ratio below 1 indicates a decrease in antibodies in the serum. This value may offer the possibility to make more informed and adaptive treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.